Compounds obtained from i(salvia) species having antiviral activity

A viral infection, virus technology, applied in the direction of antiviral agents, organic active ingredients, active ingredients of hydroxyl compounds, etc., can solve problems such as expensive diseases

Inactive Publication Date: 2001-09-12
GEORGETOWN UNIV
View PDF20 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] Treating virus-mediated diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compounds obtained from i(salvia) species having antiviral activity
  • Compounds obtained from i(salvia) species having antiviral activity
  • Compounds obtained from i(salvia) species having antiviral activity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0064] Extraction of antiviral agents from SM and SY

[0065] Plant extracts of SM and SY were prepared as follows:

[0066] Step 1: Dry SY in Milli-Q distilled water (dH 2 O) (18.0 mOhm / cm) and concentrated to a final density of 1.30 g / ml. followed by dH 2 O The extract was diluted 1:5 and centrifuged at 8000 rpm for 90 minutes at 25°C in a GS-3 rotor. Discard the pellet and keep the supernatant. One-tenth volume of 1.0N HCl solution was added to the supernatant so that the final concentration of HCl was 0.1N. The supernatant was incubated overnight at 25°C. The solution was centrifuged in a GS-3 rotor at 8000 rpm at 25° C. for 90 minutes, and the resulting precipitate was washed with 95% ethanol and then filtered through a 0.2 μm filter system. This operation was repeated until the washing solution became clear. The precipitate was then dried on filter elements at room temperature, followed by incubation in an oven at 70°C overnight. Resuspend the powder in dHO at a ...

Embodiment 2

[0088] Antiviral Trials: Efficacy of Virus Suppression

[0089] In Vitro HIV-1 Integrase Assay: An in vitro assay for monitoring HIV-1 integrase activity has been developed as described below. These assays utilize purified recombinant HIV-1 integrase and oligonucleotide substrates representing the LTR termini of viral DNA. An important benefit of data obtained from in vitro assays is that the assays reflect actual functional activity occurring in vivo. Fluorescence assays (Lee et al., "Analytical Biochemistry" 227:295-301 (1995)) and radioactive assays have been developed to improve the in vitro assays disclosed above (Lee et al. "Biochemistry" 34:10205-10214 (1995) ); Lee et al. Biochemistry 34:10215-10223 (1995)). In addition, we improved the enzyme preparation, which increased the quality of HIV-1 integrase samples (Lee & Han, "Biochemistry" 35:3837-3844 (1996); Lee et al., "Biochemistry" 36:173-180 (1997)). The aforementioned improvements in in vitro assays a...

Embodiment 3

[0093] In vitro test of SM extract

[0094] The feline immunodeficiency virus (FIV) model is an accepted animal model for studying drugs against HIV infection. FIV is a T-cell trophic lentivirus isolated from cats. FIV is biologically and biochemically similar to HIV, including high homology between FIV and HIV integrase. FIV-infected cats develop feline acquired immunodeficiency syndrome (FAIDS), which is similar to full-fledged AIDS in humans.

[0095] In vitro FIV model in cell culture: The Crandell-Reese feline kidney (CrFK) cell line is sensitive to FIV infection and supports viral replication. CrFK cells are an efficient tool for virus production and analysis of FIV infection. Although FIV does not cause cytopathic effects in FIV-infected CrFK cells, diagnostic tests to screen for FIV infection in tissue culture are available. Research confirms the efficacy of SY.

[0096] ED 50 Determination of: The effect of part 1 on protecting CrFK cells from FIV in...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Compositions are provided containing molecules having at least one moiety from beta-(3,4-dihydroxyphenyl)lactic acid and/or caffeic acid, which are found in extracts from the plant genus Salvia, said moieties being of formula(I), the active agents having a molecular weight of at least 190 daltons. A class of preferred agents are those which are conjugated to form dimers, trimers, tetramers and larger polymers containing said moieties, with the most preferred being salvianolic acid dimers, trimers, tetramers and larger polymers. The compounds and compositions may be administered in pharmaceutically acceptable carriers and excipients systematically or locally to treat viral infections.

Description

field of invention [0001] The present invention relates to active substances obtained from extracts of plants of the genus Salvia. The active ingredient comprises a molecular conjugate having at least one moiety derived from β-(3,4-dihydroxyphenyl)lactic acid and / or caffeic acid. Preferably, the active ingredient is salvianolic acid, dimers, trimers and tetramers thereof. The active agents may be administered, either alone or more preferably in combination, for the treatment of viral infections or virus-mediated disorders. Background of the invention [0002] Salvia miltiorrhiza: Salvia miltiorrhiza has long been used in traditional Chinese medicine for the treatment of cardiovascular and liver diseases. Extracts of this plant exert potent hepatoprotective activity both in vitro and in vivo. See Hase et al., Planta Med. 63:22-6 (1997). Magnesium lithospermate B may be one of the main active ingredients in SM with hepatoprotective effect (Liu et al., Chinese Journal of In...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/05A61K31/19A61K31/192A61K31/235A61K36/537A61K36/53A61K47/48A61P31/12C08F246/00
CPCA61K31/19A61K47/48192C08F246/00A61K47/59A61P31/12Y02A50/30A61K31/192
Inventor M·K·汉恩P·李
Owner GEORGETOWN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap